Product Description
Spartalizumab is a humanized IgG4 monoclonal antibody developed by Novartis for the treatment of solid tumors as well as lymphomas. They act as negative immune regulators of programmed death-1 (PD-1), a transmembrane protein belonging to the immunoglobulin (Ig) superfamily. When administered, Spartalizumab binds to T-cells expressing PD-1 and thereby blocks the interaction between PD-1 and its ligands, programmed cell death 1 ligand 1 (PD-L1) and ligand 2 (PD-L2). Blocking the interaction disrupts PD-1 mediated signaling and results in activation of cytotoxic T lymphocytes and T cell mediated immune responses and thus inhibits the growth and size of the tumors. Ongoing clinical trials are evaluating the efficacy of this antibody for the treatment of metastatic pancreatic cancer and melanoma.
Biovision | A2131 | Anti-PD-1 (Spartalizumab), Humanized Antibody DataSheet
Antibody Target: PD-1
Target Alternative Name: PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-l, PDR 001, PDR001
Tag Line: Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1
Category: Primary antibody
Host: CHO cells
Isotype: Human IgG4
Species Reactivities:
Immunogen Sequence: Spartalizumab
Accession #:
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration:
Formulation: In PBS buffer, pH 7.2
Purification:
Application: In vivo studies
Positive Control:
Application And Usages: In vivo studies
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE